We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -0.29% | 34.80 | 34.80 | 35.00 | 35.75 | 34.80 | 35.75 | 87,693 | 12:16:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 205.00 | 188.24M |
From Apr 2019 to Apr 2024
TIDMAPH
RNS Number : 2177E
Alliance Pharma PLC
04 May 2017
For immediate release 4 May 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Changes to interests of a significant shareholder
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, has received a notification of a change in the interests of a significant shareholder. In accordance with AIM rule 17, the following details are now notified:
(a) Identity of the significant shareholder: Mr Nigel Wray
(b) Date of disclosure: 3 May 2017
(c) Date of relevant change: 3 May 2017
(d) Price, amount and class: 8,093,312 ordinary shares of 1p each; price not disclosed
(e) Nature of transaction: sale of shares
(f) Nature and extent of significant shareholder's interest: direct and indirect interests
(g) Resultant shareholding: 1.63% (direct) and 3.68% (indirect) = 5.31% total
In compliance with DTR5, a copy of the notification received from this investor is appended.
For further information:
Hot Features
Premium
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Andrew Franklin, Chief Financial
Officer
Rob Bellhouse, Company Secretary
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
/ Jane Glover
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: James
Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
---------------------------------------------------------------------------------------------------------
1. Identity of the issuer or ALLIANCE PHARMA PLC
the underlying issuer
of existing shares to which
voting rights are
attached:
------------------------------------------------------------- ------------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
---------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
-------------------------------------------------------------------------------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
-------------------------------------------------------------------------------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
-------------------------------------------------------------------------------------------------------
An event changing the breakdown of voting rights
-------------------------------------------------------------------------------------------------------
Other (please Placing shares and exercise of broker's
specify): option
------------------------------------------------------------ -----------------------------------------
3. Full name of person(s) NIGEL WRAY
subject to the
notification obligation:
------------------------------------------------------------- ------------------------------------------
4. Full name of shareholder(s) Jarvis Investment Management
(if different from 3.): Nominees Limited
UBS PRIVATE BANKING NOMINEES
LTD
ROY NOMINEES LIMITED
------------------------------------------------------------- ------------------------------------------
5. Date of the transaction 3 May 2017
and date on
which the threshold is
crossed or
reached:
------------------------------------------------------------- ------------------------------------------
6. Date on which issuer 3 May 2017
notified:
------------------------------------------------------------- ------------------------------------------
7. Threshold(s) that is/are
crossed or
reached: 5%
------------------------------------------------------------- ------------------------------------------
8. Notified details:
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------- --------------------------------- --------------------------------------------------------------------
Number Number Number Number of % of voting
of of of voting rights
Shares Voting shares rights
Rights
------------- --------------- ---------------- -------------- ------------------------- -------------------------
Direct Direct Indirect Direct Indirect
------------- ----------- ------------ -------------- ------------ ----------- ------------ -----------
Ordinary
shares
GB0031030819 33,185,905 33,185,905 7,708,005 7,708,005 17,384,588 1.63% 3.68%
--------------- ---------------- -------------- ------------ ----------- ------------ -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument Period may be
acquired if
the
instrument
is
exercised/
converted.
----------------- ------------- -------------------------------- --------------------------- ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights
instrument period refers to
--------------- ------------- -------------- ---------------- --------------------------- -----------------------
Nominal Delta
--------------- ------------- -------------- ---------------- --------------------------- ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
-------------------------------------------------- ------------------------------------------------------------------
25,092,593 5.3%
-------------------------------------------------- ------------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
---------------------------------------------------------------------------------------
Nigel William Wray has a beneficial interest in shares
in Alliance Pharma Plc held by the following nominees
7,551,269 held by UBS Private Banking Nominees Ltd
156,736- Jarvis Investment Management Nominees Limited
The family of Nigel Wray maintains a beneficial interest
in the shares held by Roy Nominees Limited - 17,384,588
Proxy Voting:
---------------------------------------------------------------------------------------
10. Name of the proxy holder: N/A
------------------------------------------------------- ------------------------------
11. Number of voting rights proxy N/A
holder will cease
to hold:
------------------------------------------------------- ------------------------------
12. Date on which proxy holder will N/A
cease to hold
voting rights:
------------------------------------------------------- ------------------------------
13. Additional information: Figures are based on a total
number of voting rights of
472,795,052
------------------------------------------------------- ------------------------------
14. Contact name: Nigel Wray
------------------------------------------------------- ------------------------------
15. Contact telephone number: 020 7647 7647
------------------------------------------------------- ------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUGUAPAUPMGPC
(END) Dow Jones Newswires
May 04, 2017 08:30 ET (12:30 GMT)
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
